Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + aflibercept in metastatic colorectal cancer patients unsuitable for intensive chemotherapy
ISRCTN10133162Phase 2Completed
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Feb 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of aflibercept and capecitabine in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Guy's and St Thomas' NHS Foundation Trust. Primary endpoints: Maximum tolerated dose and Safety and tolerability. Started Feb 2014; status: completed.
02
Drugs
afliberceptcapecitabine
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ISRCTN10133162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10133162.